SEC Form 4 · accession 0001213900-26-066290
Can-Fite BioPharma Ltd. · CANF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Motti Farbstein
Officer — CEO, CFO and COO
Period of report
Jun 4, 2026
Accepted (ET)
Jun 8, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001536196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary SharesF1,F2,F3 | $2.043 | Jun 4, 2026 | A | 24,000 | A | Sep 4, 2026 | Jun 4, 2036 | Ordinary Shares | 24,000 | 33,132 | D |
Explanation of responses
- F1To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
- F2The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- F3The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00.